
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a strong focus on developing treatments for central nervous system disorders. Its innovative drug candidate, ML-007C-MA, has shown promising results in early studies and has the potential to generate significant revenue by 2035. Additionally, the company's experienced management team and unique drug discovery platform make it a promising investment opportunity for future success in the field of neuroscience.
Bears say
MapLight Therapeutics is poised for potential success in the biopharmaceutical industry with their development of novel drugs targeting muscarinic receptors in central nervous system disorders. Despite being a clinical-stage company, their drug candidate ML-007C-MA is showing positive results in Phase 2 trials for Alzheimer's disease and schizophrenia. Additionally, their focus on developing drugs for underserved disorders such as autism spectrum disorder sets them apart from other companies in the space.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares